Last reviewed 2026-04-23 · How we verify

modified FOLFIRINOX

Modified FOLFIRINOX is a chemotherapy regimen that combines four drugs to target rapidly dividing cancer cells.

Modified FOLFIRINOX is a chemotherapy regimen that combines four drugs to target rapidly dividing cancer cells. Used for Metastatic pancreatic cancer.

At a glance

Mechanism of action

The regimen consists of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin, which work together to inhibit DNA replication and induce apoptosis in cancer cells. This combination has been shown to be effective in treating various types of cancer, including pancreatic cancer.

Approved indications

• Metastatic pancreatic cancer

Common side effects

• Neutropenia
• Diarrhea
• Nausea
• Vomiting
• Fatigue

Key clinical trials

• Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
• PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) (PHASE1, PHASE2)
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (PHASE1, PHASE2)
• GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NA)
• Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (PHASE1)
• Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (PHASE2)
• Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer (PHASE2)
• Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.